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Abstract
Background: Replacing carbohydrate with protein acutely increases glomerular filtration rate (GFR) but is associated
with faster, long-term kidney disease progression. The effects of carbohydrate type (i.e. glycemic index, GI) on kidney
function are unknown.
Methods: We conducted an ancillary study of a randomized, crossover feeding trial in overweight/obese adults
without diabetes or kidney disease (N = 163). Participants were fed each of four healthy, DASH-like diets for 5 weeks,
separated by 2-week washout periods. Weight was kept constant. The four diets were: high GI (GI ≥65) with high
%carb (58 % kcal) (reference diet), low GI (≤45) with low %carb (40 % kcal), low GI with high %carb; and
high GI with low %carb. Plasma was collected at baseline and after each feeding period. Study outcomes
were cystatin C, β2-microglobulin (β2M), and estimated GFR based on cystatin C (eGFRcys).
Results: Mean (SD) age was 52 (11) years; 52 % were women; 50 % were black. At baseline, mean (SD) cystatin
C, β2M, and eGFRcys were 0.8 (0.1) mg/L, 1.9 (0.4) mg/L, and 104 (16) mL/min/1.73 m2. Compared to the high GI/high
%carb diet, reducing GI, %carb, or both increased eGFRcys by 1.9 mL/min/1.73 m2 (95 % CI: 1.1, 2.7; P < 0.001),
3.0 mL/min/1.73 m2 (1.9, 4.0; P < 0.001), and 4.5 mL/min/1.73 m2 (3.5, 5.4; P < 0.001), respectively. Increases in
eGFRcys from reducing GI were significantly associated with increases in eGFRcys from reducing %carb (P < 0.001).
Results for cystatin C and β2M reflected eGFRcys.
Conclusions: Reducing GI increased GFR. Reducing %carb by increasing calories from protein and fat, also increased
GFR. Future studies on GI should examine the long-term effects of this increase in GFR on kidney injury markers and
clinical outcomes.
Trial registration: Clinical Trials.gov, number: NCT00608049 (first registered January 23, 2008)
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Background
Replacing dietary carbohydrates with protein increases
glomerular filtration rate (GFR) acutely and is associated
with faster chronic kidney disease (CKD) progression
over the long-term [1–3]. Whether carbohydrate quality
affects GFR is unknown. Glycemic index (GI) is a meas-
ure of carbohydrate quality, i.e. the amount of glucose
released into circulation from carbohydrate-based foods
[4]. GI is determined by comparing the area under a 2-h
glucose curve measured after consumption of a stan-
dardized amount of carbohydrates from two food items
(the food of interest and a reference food) [5]. Previous
observational studies demonstrated that higher GI is as-
sociated with prevalent CKD [6]. However, this associ-
ation has not been examined in a trial setting and could
have implications for CKD prevention.
In this analysis of data from “The Effect of Amount
and Type of Dietary Carbohydrates on Risk for
Cardiovascular Heart Disease and Diabetes Study”
(OMNICARB), we determined the effects of reducing
GI or the proportion of carbohydrates (%carb) on
GFR in relatively healthy adults, using a cystatin C
estimating equation. We further estimated GFR with a
creatinine-based equation for comparison. We hypothe-
sized that reducing GI would increase GFR as a result
of metabolic changes, and that reducing %carb (i.e. in-
creasing the proportion of protein) would increase
GFR. We reported this relationship to change in pro-
tein intake in an earlier publication from a different
feeding study (OMNI-HEART) [7]. A cystatin C-based
equation, rather than a creatinine-based equation, was
our primary outcome because of a concern that
changes in dietary protein intake would influence
serum creatinine levels and interfere with accurate esti-
mation of kidney function [7].
Methods
The rationale, design, and main effects of OMNICARB
were described previously [8]. The current ancillary
study utilized stored plasma specimens to examine the
effects of amount and type of carbohydrates on markers
of kidney function.
OMNICARB was a randomized, crossover trial, com-
prising 4-dietary interventions: high GI (GI ≥65) with
high %carb (58 % kcal from carbohydrates) (reference
diet), low GI (GI ≤45) with low %carb (40 % kcal from
carbohydrates), low GI with high %carb; and high GI
with low %carb [8]. Other key nutrients were similar
across the four diets (Table 1). By design, the diets were
healthy using the core nutrient profile of the DASH diet
[9]. Each diet was isocaloric, was prepared with com-
monly available foods, and was low in saturated fat,
cholesterol, and sodium, but rich in fruits, vegetables,
fiber, potassium, and other minerals. Note that the low
%carb diets were also higher in % protein.
Participant recruitment
Trial participants were adult men and women, residing
in and around Boston, Massachusetts, and Baltimore,
Maryland. Participants were ≥30 years, had a body mass
index ≥25 kg/m2 with a systolic BP of 120–159 and a
diastolic BP <100 mmHg. Persons with a prior diagno-
sis of diabetes or cardiovascular disease were excluded
[8]. Persons were also excluded if they had renal insuffi-
ciency on screening labs, based on an estimated GFR
<40 ml/min per 1.73 m2. Similarly, participants were
Table 1 Nutrient composition of the four diets used in OmniCarba








Energy, kcal 2011 1998 2011 1993
Glycemic Index 66 41 65 40
Carbohydrates, % kcal 58 57 41 40
Protein, % kcal 16 16 23 23
Fat, % kcal 27 27 37 37
Saturated, % kcal 6 6 7 7
Monounsaturated, % kcal 12 13 18 19
Polyunsaturated, % kcal 7 8 10 10
Fiber, g 32 37 29 33
Cholesterol, mg 90 89 170 163
Calcium, mg 1032 1051 993 995
Potassium, mg 3963 4103 3949 4026
Sodium, mg 2245 2211 2305 2199
Magnesium, mg 462 429 468 440
aEstimated from food analysis software (ESHA Food Processor SQL, version 10.2, ESHA Research)
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deemed eligible for inclusion if baseline systolic blood
pressure was 120–159 mmHg and diastolic blood pres-
sure was <100 mmHg (mean over three screening
visits). Anyone with stage 2 hypertension (systolic
blood pressure > 160 or diastolic blood pressure >
100 mmHg) based on the mean of three screening visits
were excluded. Anyone with a mean systolic blood
pressure >170 or diastolic blood pressure >105 mmHg
at any one visit were also excluded [8]. Institutional Re-
view Boards approved the study protocol, and all partic-
ipants provided written informed consent.
Controlled feeding
Controlled feeding began in August 2008 and was com-
pleted in December 2010. Participants were randomly
assigned to 1 of 8 dietary sequences of the 4 diets [8].
Feeding periods lasted for 5 weeks, separated by 2-week
washout periods. Calorie targets were determined for
each participant based on body size, sex, and physical
activity level. Participants were provided all of their
foods and caloric intake was adjusted to maintain weight
within 2 % of participants’ baseline values. Participants
were encouraged to maintain the same activity levels
and alcohol consumption throughout the study. Every
day, participants ate at least one meal at the study
site and meal attendance and meal consumption were
monitored. Participants also completed a diary in
which they listed any consumption of non-protocol
foods. Biochemical markers of dietary compliance
were urine urea nitrogen, urine creatinine, urine so-
dium, and urine potassium.
Measurement of outcomes
Laboratory specimens were collected for each partici-
pant at baseline and at the completion of each 5-week
feeding period. Cystatin C, β2 microglobulin (β2M), and
creatinine were measured in plasma samples that were
collected in tubes, centrifuged, and stored at −70 °C.
Cystatin C and β2M were used to estimate kidney func-
tion, whereas plasma creatinine and estimated glomeru-
lar filtration rate based on creatinine (eGFRcreat) were
measured for purposes of comparison. When compared
to creatinine, these markers are less influenced by fac-
tors know to affect creatinine such as race [10] and diet
(e.g. protein intake) [7]. Both cystatin C and β2M were
measured with particle-enhanced immunonephelometric
assays (N Latex Cystatin C assay and N Latex β2M
assay, Dade Behring, IL). Inter-assay coefficients of vari-
ation for cystatin C and β2M were 2.0 % (mean
0.917 mg/L) and 1.8 % (mean 2.184 mg/L), respectively.
Creatinine was measured in stored plasma specimens
using standardized laboratory assays with an inter-assay
coefficient of variation of 6.6 % (mean 0.653 mg/dL).
Glomerular filtration rate was estimated using the
Chronic Kidney Disease Epidemiology Collaboration
cystatin C-based equation (eGFRcys) [11] and the
Chronic Kidney Disease Epidemiology Collaboration
creatinine-based GFR equation (eGFRcreat) [12]. As op-
posed to other estimating equations, these equations
were used because they were developed in a population
sample that included individuals, who like the partici-
pants of the OMNICARB trial, did not have chronic
kidney disease (CKD).
Other covariate measurements and definitions
Additional laboratory and physical exam covariates were
determined as follows. Body mass index (BMI) was cal-
culated using baseline height and weight measurements
and was dichotomized as 25–29.9 kg/m2 or ≥30 kg/m2.
Waist circumference (cm) was measured at the level of
the umbilicus. Fasting glucose and insulin were mea-
sured at baseline and at the end of each feeding period.
The homeostasis model assessment index (HOMA) was
calculated using HOMA= [(fasting serum insulin con-
centration in μU/mL) x (fasting serum glucose concen-
tration in mmol/L)]/22.5 and dichotomized based on the
baseline median value of ≥1.48. Similarly, traditional as-
says were used to measure total triglycerides and HDL
cholesterol. LDL cholesterol levels were estimated by the
Friedewald equation [13]. Triglycerides were dichoto-
mized using the baseline median value of 83.8 mg/dL.
Uric acid and high sensitivity C-reactive protein were
also measured in plasma collected at baseline and the
end of each feeding period.
Baseline hypertension status (yes or no) was deter-
mined by an average of 3 baseline blood pressure
measurements in which systolic blood pressure was
>140 mmHg or diastolic blood pressure was >90 mmHg.
No participants were taking antihypertensive medications.
Blood pressure was also measured at the end of each feed-
ing period as the average of 3 measurements by trained
and certified staff using a validated automated oscillo-
metric OMRON 907 device.
Mediators of glomerular filtration
At baseline and at the end of each feeding period, we
assessed potential mediators of glomerular filtration, in-
cluding markers of glucose homeostasis (fasting glucose,
insulin, triglycerides), endothelial function (uric acid,
systolic BP, diastolic BP), and inflammation (high sensi-
tivity C-reactive protein).
Statistical analysis
The primary outcomes examined in this study were
cystatin C, β2M, and eGFRcys. We estimated change
from baseline for each of the 4 diets. Using the high
%carb, high GI diet as a reference, we then calculated
the effects of reducing GI alone, %carb alone, or both GI
Juraschek et al. BMC Nephrology  (2016) 17:70 Page 3 of 10
and %carb for each outcome and generated forest plots
for visual representation. In addition, we performed
stratified analyses by covariates known to be associated
with insulin resistance, namely, race (non-Hispanic black
versus white), baseline hypertension status, baseline tri-
glycerides, baseline BMI, and baseline HOMA. All of the
above comparisons were performed via generalized esti-
mating equation (GEE) regression models, using a
Huber and White robust variance estimator [14], which
assumed an exchangeable working correlation matrix.
P-values for each stratum were generated using inter-
action terms. The above analyses were repeated for
creatinine and eGFRcreat for comparison.
We also used linear regression to determine
whether the change in eGFRcys which resulted from
reducing GI was associated with change in eGFRcys
which resulted from reducing %carb. A positive asso-
ciation would suggest a common mechanism of action
for GI and %carb on kidney function. We further per-
formed a mediation analysis of eGFRcys, adjusting for
concurrent changes in markers of glucose homeostasis
(fasting glucose, insulin, triglycerides), endothelial
function (uric acid, systolic blood pressure, diastolic
blood pressure), and inflammation (high sensitivity C-
reactive protein), all thought to influence GFR.
For dietary compliance measures, namely, urine
urea nitrogen, urine creatinine, urine sodium, and
urine potassium, we performed baseline and between-
diet comparisons only, using similar models described
above. A sensitivity analysis using feeding period 1
alone was conducted to eliminate potential carryover
effects. We also performed a sensitivity analysis exam-
ining every possible dietary comparison grouped by
GI, %carb, or simultaneous changes in both GI and
%carb. The purpose of this analysis was to confirm
our primary comparison between diets, which utilized
the high GI, high %carb diet as our reference group.
All analyses were performed in STATA version 11.1
(Stata Corporation, College Station, TX, USA). Statis-
tical significance was defined as P ≤ 0.05. Missing data
specimens were excluded from analyses as they were
few (N = 4) and evenly distributed between feeding
periods and diets.
Results
Baseline characteristics of the randomized, study popula-
tion are shown in Table 2. Overall mean age was 52.1 ±
11.4 years; 52 % of the participants were women, and
50 % were non-Hispanic blacks. Furthermore, 56 % of
participants were obese, and 26 % had hypertension.
End-of-period measures were compared to baseline
measures (Table 3). Cystatin C was significantly
greater during the high GI, high %carb diet (P =0.04)
and significantly lower during the high GI/low %carb,
and low GI/low %carb diets (both P ≤0.001). β2M was
significantly lower during the low GI/low %carb diet
(P =0.002). While eGFRcys decreased significantly
~1 mL/min/1.73 m2 during the high GI/high %carb
diet (P =0.02), it increased significantly during the high
GI/low %carb (~2 mL/min/1.73 m2; P =0.002) and low
GI/low %carb diets (~3 mL/min/1.73 m2; P <0.001).
Creatinine did not change significantly during any
dietary period throughout the trial. There was no sig-
nificant difference between end-of-period eGFRcreat
and baseline during any of the four diets.
When compared with baseline, urine urea nitrogen
was significantly higher during the low %carb diets
(P <0.001 for high GI/low %carb and P <0.001 for low
GI/low %carb) consistent with the higher protein
composition of these diets. Urine creatinine tended
to decrease during the high %carb diets (P =0.12 for
high GI/high %carb and P =0.01 for low GI/high
Table 2 Baseline characteristics of trial participants (N = 163),
mean ± SD or No. (%)
Age, y 52.1 ± 11.4
Women 85 (52)
Race
Non-Hispanic White 66 (40)
Non-Hispanic Black 82 (50)
Hispanic 11 (7)
Asian 4 (2)
Body mass index, kg/m2 32.3 ± 5.5
Body mass index
25–29.9 71 (44)
≥ 30 92 (56)
Waist circumference, cm 104.4 ± 13.5
Fasting glucose, mg/dL 97.3 ± 13.6
Fasting insulin, μU/mL 7.7 ± 5.8
Homeostasis model assessment (HOMA), units 1.9 ± 1.6
Triglycerides, mg/dL 104.6 ± 67.1
HDL cholesterol, mg/dL 58.3 ± 16.0
LDL cholesterol, mg/dL 153.0 ± 42.1
Systolic blood pressure, mm Hg 132.0 ± 9.1
Diastolic blood pressure, mm Hg 80.0 ± 7.5
Baseline hypertension statusa
No hypertension 120 (74)
Hypertension 43 (26)
Uric acid, mg/dLb 4.7 ± 1.2
High sensivity C-reactive protein, mg/Lb 3.2 ± 4.0
aDefined as baseline SBP ≥ 140 or DBP ≥ 90 mmHg
bOnly measured in 159 participants due to lost specimens
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Table 3 Plasma markers of kidney function and urine markers of compliance, N = 159
Mean (95 % Confidence Interval) change from baseline by diet
High carbohydrate, high glycemic
index diet
High carbohydrate, low glycemic
index diet
Low carbohydrate, high glycemic
index diet
Low carbohydrate, low glycemic
index diet
Baseline Mean (SD) Difference, 95 % CI P Difference, 95 % CI P Difference, 95 % CI P Difference, 95 % CI P
Cystatin C, mg/L 0.8 (0.1) 0.01 (0.00, 0.02) 0.04 −0.01 (−0.02, 0.00) 0.13 −0.02 (−0.03,–0.01) 0.001 −0.03 (−0.04,–0.03) <0.001
B2-microglobulin, mg/L 1.9 (0.4) 0.04 (−0.01, 0.08) 0.10 0.00 (−0.04, 0.03) 0.86 −0.04 (−0.07, 0.00) 0.06 −0.05 (−0.09,–0.02) 0.002
Creatinine, mg/dL 0.8 (0.2) −0.01 (−0.02, 0.00) 0.15 −0.01 (−0.03, 0.00) 0.14 0.01 (−0.01, 0.03) 0.21 −0.01 (−0.02, 0.01) 0.25
eGFRcys, mL/min/1.73 m2 104.2 (16.0) −1.19 (−2.19,–0.18) 0.02 0.71 (−0.20, 1.63) 0.13 1.78 (0.67, 2.90) 0.002 3.28 (2.32, 4.24) <0.001
eGFRcreat, mL/min/1.73 m2 100.1 (16.4) 0.60 (−0.71, 1.91) 0.37 0.83 (−0.57, 2.23) 0.24 −0.87 (−2.44, 0.69) 0.27 0.67 (−0.82, 2.15) 0.38
Urine nitrogen, mg/d 10116.4 (4767.7) −13.0 (−769.4, 743.5) 0.97 257.8 (−500.7, 1016.2) 0.51 3734.9 (2821.3, 4648.4) <0.001 3852.6 (2946.7, 4758.5) <0.001
Urine creatinine, mg/d 1463.9 (592.7) −71.2 (−160.0, 17.7) 0.12 −117.3 (−204.6, −30.0) 0.01 37.5 (−59.4, 134.4) 0.45 −9.3 (−109.0, 90.3) 0.86
Urine sodium, mmol/d 152.9 (77.7) −31.4 (−44.1, −18.7) <0.001 −38.6 (−51.3, −25.9) <0.001 −29.5 (−41.6, −17.5) <0.001 −35.5 (−48.9, −22.1) <0.001
Urine potassium, mmol/d 56.9 (26.2) 19.8 (14.6, 24.9) <0.001 19.7 (14.6, 24.8) <0.001 19.3 (14.3, 24.2) <0.001 16.9 (11.0, 22.7) <0.001












%carb), consistent with the diets’ lower protein com-
position (16 % vs. 23 %). For all diets, urine sodium
significantly decreased and urine potassium increased
(all P-values <0.001). This was expected given the
low sodium and high fruits and vegetable-based
foods inherent in all the OMNICARB diets.
The effects of reducing GI or %carb on β2M, cysta-
tin C, and eGFRcys were compared across diets, using
the high GI,/high %carb diet as a reference (Fig. 1a-c). Re-
ducing GI, %carb, or both GI and %carb significantly
reduced cystatin C (P <0.001 for all three) and β2M
(P <0.001 for all three). Each of the diets significantly
increased eGFRcys (P <0.001 for all three). Further-
more, the magnitude of effect was higher, ranging
from ~2 mL/min/1.73 m2 (reduced GI) and ~3 mL/
min/1.73 m2 (reduced %carb) to 4.5 mL/min/1.73 m2,
when both GI and %carb were reduced.
The effects of dietary carbohydrates on plasma cre-
atinine and eGFRcreat were also assessed (Additional
file 1: Figure S1A-B). While reducing %carb increased
serum creatinine (P = 0.001), increased urine creatin-
ine excretion (P = 0.007), and decreased eGFRcreat by
1.5 mL/min/1.73 m2 (P = 0.02), reducing GI or both
factors had no effect on serum creatinine, urine cre-
atinine excretion, or eGFRcreat.
In general, the observed effects on kidney markers
and GFR described above were confirmed when every
possible dietary comparison was performed with the
exception of creatinine and eGFRcreat, which
demonstrated greater variability from changes in dietary
factors (i.e. GI or %carb) (Additional file 1: Table S3).
We compared the diets’ effects on cystatin C, β2M,
creatinine, eGFRcys, and eGFRcreat by strata of factors
associated with CKD (Additional file 1: Table S1).
There was no evidence of interactions by race, hyper-
tension status, baseline triglycerides, BMI, and HOMA
on any of the observed dietary effects. A sensitivity ana-
lysis utilizing feeding period 1 alone may be found in
Additional file 1: Table S2. While the patterns of associ-
ation were unaltered, our results were attenuated when
we restricted our analysis to feeding period 1 only.
Finally, we specifically examined the mechanism by
which GI and %carb affected eGFRcys. We found that
the renal response to reducing GI was significantly
associated with the renal response to reducing %carb
(P < 0.001) (Additional file 1: Figure S2). Further, the
effects of reducing GI or %carb on eGFRcys were
only mildly attenuated with adjustment for potential
mediators of kidney function, specifically, fasting glu-
cose, insulin, triglycerides, uric acid, systolic blood
pressure, and diastolic blood pressure (Table 4).
Discussion
For the first time in a trial setting, we demonstrated
that reducing GI, i.e. changing the type of carbohydrate,
reduced markers of kidney function and increased
glomerular filtration. Furthermore, this study confirmed
prior observations that reducing %carb (i.e. increasing
Fig. 1 The effects (95 % confidence intervals) of reducing glycemic index (GI), reducing the proportion of carbohydrates (%carb), or
reducing both GI and %carb on: a cystatin C (mg/L), b β2-microglobulin (mg/L), and c cystatin C-based estimated glomerular filtration
rate (eGFRcys) (mL/min/1.73 m2) measured at the end of each feeding period. The reference diet was the high GI/high %carb diet
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%protein/fat), increases kidney function. Moreover, an
increase in eGFRcys from reducing GI tended to have a
similar effect as that observed from reducing %carb,
and these effects were additive, such that reducing both
GI and %carb increased eGFRcys by 4.5 mL/min/
1.73 m2. The effects persisted after adjustment for po-
tential mediators of kidney function.
In our study, replacing carbohydrates with fat and pro-
tein increased GFR as estimated by cystatin C and β2M.
These results are consistent with previous studies that
test dietary effects on GFR [7]. Animal and human stud-
ies have indicated that dietary protein increases renal
blood flow and glomerular filtration rates via increased
intraglomerular pressures, leading to progressive glom-
erular sclerosis, particularly in the setting of decreased
nephron mass [15–19]. These effects may be mediated
by dietary effects on signaling molecules of the tubulo-
glomerular feedback system, responsible for arteriolar
constriction [20–22]. It is also believed that dietary pro-
tein may increase neuronal nitric oxide synthase in
the kidney cortex, which relaxes the afferent renal ar-
teriole [23, 24]. Although fat was also higher in the
low carbohydrate/high protein diet, there is much less
evidence for a relationship between a higher fat diet
and hyperfiltration [25], though some have hypothe-
sized that such an association could be mediated
through inflammation [26, 27].
This study is among the first to examine the effects
of GI on GFR. GI, a metric of carbohydrate quality
determined by measuring the amount of glucose re-
leased into circulation after consumption of a stand-
ard amount of carbohydrates [4], could influence
kidney function. Reducing GI has been reported to
decrease inflammation [28]. Furthermore, animal
models have shown that a high GI diet contributes to
glomerular degeneration [29]. Recently, an observational
study of 2,600 adults reported a cross-sectional association
between dietary GI and an estimated GFR <60 mL/min
per 1.73 m2 (OR = 1.55 [1.07–2.26]; P-trend =0.01), but
dietary GI was not associated with incident CKD over
a 5-year follow-up period [6]. Contrary to the above
studies and our a priori hypothesis, we found that a
lower GI diet decreased kidney filtration markers and
increased eGFRcys. While the exact mechanism for
this observation is unknown, several animal models
have reported an association between complex carbo-
hydrates (i.e. low GI foods) and improved renal endo-
thelial nitric oxide synthase [30, 31] or decreased
leukocyte binding with glomerular endothelial cells
[32]. Whether or not the increased GFR observed in
conjunction with the low GI diets contributes ad-
versely to clinical outcomes long-term remains to be
determined.
Our study suggests that reducing GI or %carb share a
common pathway for affecting eGFRcys (Additional file
1: Figure S2). These changes are independent of markers
of plasma glucose homeostasis, endothelial function, and
inflammation, implying that dietary carbohydrates may
Table 4 Change in estimated glomerular filtration rate based on cystatin C adjusted for fasting glucose, fasting insulin, fasting
triglycerides, uric acid, systolic blood pressure, diastolic blood pressure, and high sensitivity C-reactive protein
Reducing glycemic index Change in eGFRcys (95 % CI) P
eGFRcys, mL/min/1.73 m2, unadjusted 1.90 (1.10, 2.70) <0.001
Adjusted for fasting glucose, insulin, triglycerides 1.82 (1.01, 2.63) <0.001
Adjusted for uric acid, systolic blood pressure, diastolic blood pressure 1.47 (0.70, 2.23) <0.001
Adjusted for high sensitivity C-reactive protein 1.89 (1.09, 2.69) <0.001
Adjusted for all the above 1.38 (0.62, 2.15) <0.001
Reducing carbohydrate proportion
eGFRcys, mL/min/1.73 m2, unadjusted 2.97 (1.93, 4.01) <0.001
Adjusted for fasting glucose, insulin, triglycerides 2.51 (1.45, 3.56) <0.001
Adjusted for uric acid, systolic blood pressure, diastolic blood pressure 3.27 (2.28, 4.25) <0.001
Adjusted for high sensitivity C-reactive protein 2.96 (1.92, 4.00) <0.001
Adjusted for all the above 2.84 (1.83, 3.86) <0.001
Reducing both glycemic index and carbohydrate proportion
eGFRcys, mL/min/1.73 m2, unadjusted 4.47 (3.49, 5.44) <0.001
Adjusted for fasting glucose, insulin, triglycerides 3.88 (2.84, 4.92) <0.001
Adjusted for uric acid, systolic blood pressure, diastolic blood pressure 4.14 (3.22, 5.05) <0.001
Adjusted for high sensitivity C-reactive protein 4.50 (3.54, 5.46) <0.001
Adjusted for all the above 3.67 (2.70, 4.64) <0.001
Note: eGFRcys represents estimated glomerular filtration rate-based on cystatin C
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have a direct effect on glomerular filtration [33]. We
suspect that these short-term increases in glomerular fil-
tration from reducing GI and/or %carb, represent hyper-
filtration, a maladaptive response to abnormal renal
hemodynamics and a harbinger of kidney injury and
kidney disease progression [34, 35]. The long-term im-
pact of these short-term changes in eGFRcys on clinical
outcomes is unknown. Novel markers of kidney injury in
urine [36] may help elucidate the benefit or harm of
dietary carbohydrates in future studies.
Cystatin C and β2-microglobulin (β2M) are low mo-
lecular mass plasma proteins that are alternative markers
to creatinine for estimating GFR and predicting CKD
progression [37–39]. Both cystatin C and β2M are gen-
erated at a constant rate by all nucleated cells, freely fil-
tered by glomeruli, then reabsorbed and metabolized by
the proximal tubule with minimal reentry to the blood-
stream [40–43]. Serum creatinine reflects GFR, but as a
byproduct of protein metabolism it is influenced by diet-
ary protein [7] while cystatin C and β2M do not seem to
be influenced by dietary protein [7, 16, 39]. Hence, these
markers represent an attractive alternative to creatinine
for quantifying GFR in feeding studies that involve
changes in dietary protein [7].
In this trial, both cystatin C and β2M were affected
by OMNICARB diets in a similar fashion, that is, lower
%carb/higher protein or lower GI decreased plasma
concentrations of both cystatin C and β2M. In contrast,
creatinine did not decline with lower GI and further in-
creased during the low %carb (higher protein)/high GI
diet. In absence of measured GFR, this could be inter-
preted as either non-GFR effects on both cystatin C
and β2M or non-GFR effects on creatinine. These ob-
served effects had important ramifications on estimated
GFR, which was significantly increased when estimated
using cystatin C, but null or decreased when estimated
using creatinine. Given the independent biosynthetic
pathways of each of these three markers, it is more
probable that non-GFR effects would influence one ra-
ther than two markers [10], that is in this case, creatin-
ine versus both cystatin C and β2M. This underscores
the value of non-traditional markers in better estimat-
ing changes in GFR [10, 44].
This study has limitations. The feeding periods were
too brief to observe dietary effects on clinical events.
Furthermore, the study did not include patients with
diabetes or CKD, populations that might demonstrate
greater changes in kidney function from alterations in
dietary carbohydrates. Moreover, the diets were all
DASH-like, healthful diets. It is possible that greater ef-
fects on kidney function would be observed if the refer-
ence diet was a typical American diet. Finally, it should
be noted that by design reductions in %carb intake were
coupled with increases in both fat and protein to keep
overall caloric intake constant between diets. Thus, it
would be inaccurate to conclude that reducing %carb
alone increased kidney function. A better interpretation
would be that replacing calories from carbohydrates with
calories from protein and fat increased kidney function.
This study also has strengths, including being an
ancillary of a randomized trial with a diverse popula-
tion and high follow-up rates that obtained repeat
measures of kidney function. Diets were tightly con-
trolled and isocaloric, eliminating the potential effect
of weight change on outcomes. Furthermore, we uti-
lized alternative kidney markers instead of creatinine,
which permitted more accurate assessments of diet-
induced changes in GFR [7].
Conclusion
In conclusion, we found that both a low GI and low
%carb (i.e. higher protein/fat) diets increased GFR,
which possibly reflects hyperfiltration or risk of kidney
injury. At this point it is unclear whether the increase in
GFR caused by low GI diets would be associated with
adverse clinical outcomes. This should be an important
focus of future studies on GI and kidney function.
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Additional file 1: Figure S1. The effects (95% confidence intervals)
of reducing glycemic index (GI), reducing the proportion of carbohydrates
(%carb), or reducing both GI and %carb on: (A) creatinine (mg/dL) and (B)
creatinine-based estimated glomerular filtration rate (eGFRcreat) (mL/min/
1.73 m2) measured at the end of each feeding period. Figure S2. Scatter
plot of the change in cystatin C-based estimated glomerular filtration rate
(eGFRcys) (mL/min/1.73 m2) from reducing glycemic index (y-axis) versus
reducing proportion of carbohydrate (x-axis). A linear regression line (dashed
line) overlays the data (P-value of the coefficient was < 0.001). Table S1.
Baseline change in glomerular filtration markers by subgroup (reference diet
is the high glycemic index, high carbohydrate diet). Table S2. Between Diet
Comparison Restricted to Visit 1 Only. Table S3. All Between Diet
Comparisons. (DOCX 165 kb)
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